Show simple item record

dc.contributor.authorBrand, DH
dc.contributor.authorKirby, AM
dc.contributor.authorYarnold, JR
dc.contributor.authorSomaiah, N
dc.date.accessioned2022-04-19T11:30:24Z
dc.date.available2022-04-19T11:30:24Z
dc.identifier.citationClinical oncology (Royal College of Radiologists (Great Britain)), 2022, 34 (5), pp. 280 - 287en
dc.identifier.issn0936-6555
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5089
dc.identifier.eissn1433-2981en_US
dc.identifier.eissn1433-2981
dc.identifier.doi10.1016/j.clon.2022.02.009en_US
dc.identifier.doi10.1016/j.clon.2022.02.009
dc.description.abstractHypofractionated radical radiotherapy is now an accepted standard of care for tumour sites such as prostate and breast cancer. Much research effort is being directed towards more profoundly hypofractionated (ultrahypofractionated) schedules, with some reaching UK standard of care (e.g. adjuvant breast). Hypofractionation exerts varying influences on each of the major clinical end points of radiotherapy studies: acute toxicity, late toxicity and local control. This review will discuss these effects from the viewpoint of the traditional 5 Rs of radiobiology, before considering non-canonical radiobiological effects that may be relevant to ultrahypofractionated radiotherapy. The principles outlined here may assist the reader in their interpretation of the wealth of clinical data presented in the tumour site-specific articles in this special issue.en_US
dc.formatPrint-Electronicen_US
dc.format.extent280 - 287en_US
dc.languageengen_US
dc.language.isoengen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.subjectBreasten_US
dc.subjectHumansen_US
dc.subjectBreast Neoplasmsen_US
dc.subjectProstatic Neoplasmsen_US
dc.subjectTreatment Outcomeen_US
dc.subjectRadiobiologyen_US
dc.subjectMaleen_US
dc.subjectRadiation Dose Hypofractionationen_US
dc.titleHow Low Can You Go? The Radiobiology of Hypofractionation.en
dc.typeJournal Article
dcterms.dateAccepted2022-02-11
rioxxterms.versionVoRen
rioxxterms.versionofrecord10.1016/j.clon.2022.02.009en
dc.relation.isPartOfClinical oncology (Royal College of Radiologists (Great Britain))en_US
pubs.issue5en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Breast Cancer Radiotherapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Breast Cancer Radiotherapy/Breast Cancer Radiotherapy (hon.)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Stereotactic and Precision Body Radiotherapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Breast Radiobiology
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/17/18 Starting Cohort
pubs.publication-statusAccepteden_US
pubs.volume34en_US
pubs.embargo.termsNot knownen_US
icr.researchteamBreast Cancer Radiotherapy
icr.researchteamStereotactic and Precision Body Radiotherapy
icr.researchteamTranslational Breast Radiobiology
dc.contributor.icrauthorKirby, Annaen_US
dc.contributor.icrauthorSomaiah, Navitaen_US
dc.contributor.icrauthorBrand, Douglasen_US


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/